The purpose of this study is to assess safety, PK, Pharmacodynamic profile of a single dose of HRS-3095 in healthy participants
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
36
Veritus Research
Bayswater, Victoria, Australia
RECRUITINGSafety and Tolerability Based on Incidence and Severity of Treatment Emergent Adverse Events
Number of participants with Adverse events and Serious adverse events
Time frame: Day 8
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - Cmax
Maximum observed plasma concentration (Cmax)
Time frame: Day 4
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - AU0-inf
Area under the plasma concentration-time curve from time 0 extrapolated to infinity (AUC₀0-inf)
Time frame: Day 4
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - Tmax
Time to reach maximum observed plasma concentration (Tmax)
Time frame: Day 4
PK Profile of HRS-3095 After a Single-Dose Administration, Pharmacokinetics - t½
Terminal elimination half-life (t1/2)
Time frame: Day 4
PD Profile of HRS-3095 After a Single dose administration:
Target occupancy assessment
Time frame: Day 8
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.